New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
16:12 EDTMRK, MDVNMedivation names Dawn Svoronos as Chief Commercial Officer
Medivation (MDVN) announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, CEO and president of Medivation. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. (MRK), where she oversaw commercial operations in approximately 30 EU and EU accession countries. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities.
News For MDVN;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
11:37 EDTMRKMerck weekly volatility elevated into Q4 and outlook
Subscribe for More Information
06:34 EDTMRKObama to propose $215M for major medical program, CNBC says
Subscribe for More Information
January 29, 2015
09:07 EDTMRKHead researchers of Vertex, Regeneron, Merck invited to White House, CNBC says
Subscribe for More Information
07:58 EDTMDVNMedivation price target raised to $128 from $112 at Stifel
After surveying 25 urologists, Stifel believes that MEdivation's (MDVN) Xtandi drug has surpassed its main competitor, Johnson & Johnson's (JNJ) Zytiga, as a treatment of prostate cancer prior to chemotherapy. Stifel keeps a Buy rating on Medivation.
January 26, 2015
08:31 EDTMRKMerck says CHMP issues positive opinion for Sivextro
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO for the treatment of acute bacterial skin and skin structure infections in adults. Merck acquired SIVEXTRO as a part of its purchase, through a subsidiary, of Cubist Pharmaceuticals, Inc. The CHMP positive opinion will be reviewed by the European Commission. If the European Commission affirms the CHMP opinion, it will grant a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein and Norway. SIVEXTRO is a once-daily oxazolidinone antibiotic developed for both intravenous and oral administration for the treatment of serious infections caused by certain Gram-positive bacteria.
January 23, 2015
10:02 EDTMDVNOn the Fly: Analyst Initiation Summary
Subscribe for More Information
09:02 EDTMDVNMedivation recent weakness a buying opportunity, says UBS
Subscribe for More Information
06:39 EDTMRKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
January 22, 2015
16:15 EDTMDVNMedivation initiated with a Sector Perform at RBC Capital
Subscribe for More Information
09:16 EDTMDVNOn The Fly: Pre-market Movers
Subscribe for More Information
07:13 EDTMDVNMedivation up 1.2% after Phase 2 TERRAIN trial achieved primary endpoint
07:12 EDTMDVNMedivation phase 2 TERRAIN trial achieved primary endpoint
Subscribe for More Information
January 21, 2015
10:16 EDTMRKLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
08:02 EDTMRKMerck completes tender offer to acquire Cubist
Merck (MRK) announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals (CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7% of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares. Following consummation of the tender offer, Merck expects to complete the acquisition of Cubist later today through a merger of Merckís wholly owned subsidiary with and into Cubist without stockholder approval. Upon completion of the merger, all outstanding shares of common stock of Cubist, other than shares held by Cubist in treasury or shares held by Cubistís stockholders who are entitled to and properly exercise appraisal rights under Delaware law, will be canceled and converted into the right to receive cash equal to the $102.00 offer price per share without interest, less any applicable withholding taxes. In addition, upon completion of the merger, Cubist will become a wholly owned subsidiary of Merck and the common stock of Cubist will cease to be traded on the NASDAQ Stock Market.
January 20, 2015
17:18 EDTMRKDana Holding to replace Cubist in S&P 400 as of 1/22 close
Subscribe for More Information
07:23 EDTMRKMerck funding testing of lower dosages of Zilmax, Reuters reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use